What is Immunome?
Immunome operates at the forefront of biopharmaceutical innovation, utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics. The company's strategic focus is on addressing critical unmet needs in oncology and infectious diseases, including the development of novel treatments for COVID-19. By leveraging the immune system's memory B cells from patients who have naturally fought off diseases, Immunome aims to identify potent therapeutic antibodies and their targets, positioning itself as a key player in the evolving landscape of disease intervention.
How much funding has Immunome raised?
Immunome has raised a total of $201.4M across 8 funding rounds:
Debt
$846K
Debt
$892K
Private Equity
$3.6M
Series A
$5M
Debt
$350K
Stock Offering
$39M
Share Placement
$27M
Share Placement
$124.7M
Debt (2010): $846K, investors not publicly disclosed
Debt (2014): $892K, investors not publicly disclosed
Private Equity (2015): $3.6M, investors not publicly disclosed
Series A (2016): $5M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Stock Issuance/Offering (2020): $39M, investors not publicly disclosed
Share Placement (2021): $27M, investors not publicly disclosed
Share Placement (2023): $124.7M, investors not publicly disclosed
What's next for Immunome?
The substantial enterprise-level funding and recent strategic investment signal a pivotal moment for Immunome, likely enabling accelerated clinical development, expansion of its therapeutic pipeline, and further validation of its discovery engine. This capital infusion is expected to fuel the progression of its oncology and infectious disease programs, potentially leading to significant advancements in patient care and market penetration. The company's commitment to leveraging unique immunological insights suggests a trajectory aimed at establishing new standards in antibody-based therapies.
See full Immunome company page
